** Shares of eye-disease focused Eyenovia EYEN.O fall 2.4% to $1.63 premarket
** Co says it is exploring a reverse merger with privately held Betaliq to combine their eye-disease focused operations
** The proposed deal values Betaliq at around $77 million and Eyenovia at about $15 million
** EYEN will hold 16.3% of the combined company and Betaliq will hold the remaining stake, if merger is successful
** Both EYEN's Optejet device and Betaliq's EyeSol technology are used to deliver FDA-approved eye-care medications to patients
** Up to last close, EYEN fell ~2x in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.